Hepatic Metabolism Bypass
Hepatic Metabolism Bypass - Related Videos
07:54
Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy
0 Views •
Cited by 6 •
2011
A progressive colonization procedure is described to further assess its impact on the host hepatic metabolism. Colonization is monitored non invasively by evaluating the urinary excretion of microbial co-metabolites by NMR-based metabolic profiling while hepatic metabolism is assessed by High Resolution Magic Angle Spinning (HR MAS) NMR profiling of intact biopsy.
07:37
Roux-en-Y Gastric Bypass Operation in Rats
0 Views •
Cited by 45 •
2012
Numerous studies using gastric bypass rat models have been recently conducted to uncover the underlying physiological mechanisms of Roux-en-Y gastric bypass operations. This article aims to demonstrate and discuss the technical and experimental details of our published gastric bypass rat model to understand advantages and limitations of this experimental tool.
08:08
Cardiopulmonary Bypass in a Mouse Model: A Novel Approach
0 Views •
Cited by 9 •
2017
This paper describes how to perform cardiopulmonary bypass in mice. This novel model will facilitate the investigation of the molecular mechanisms involved in organ damage.
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
0 Views •
Cited by 28 •
2017
Here, optimized methods to generate in vivo and in vitro models of hepatic steatosis and to analyze the steatotic phenotypes and related physiological parameters are described.
01:14
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
0 Views •
2025
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
FAQs
The route determines how much of a dose encounters liver enzymes before reaching systemic circulation. Intravenous, sublingual, transdermal, inhaled, and selected rectal routes can reduce presystemic loss, but they do not provide an identical degree of bypass. The resulting effect depends on both the route selected and the drug being administered.
Reducing first-pass metabolism can preserve a greater fraction of the administered active dose for systemic circulation. This may increase bioavailability, meaning the proportion of drug reaching the bloodstream, and can support faster or more predictable effects. Consequently, pharmacologists must consider presystemic loss when interpreting exposure and selecting an appropriate dose.
Cytochrome P450 proteins are among the liver enzymes that transform orally administered drugs during their initial passage through the liver. Limiting that early exposure can reduce the amount of drug converted before it reaches the bloodstream. This enzymatic context explains why changing administration route can alter active drug availability without changing the drug itself.
Pharmacologists may consider intravenous, sublingual, transdermal, inhaled, or selected rectal administration when the goal is to reduce presystemic hepatic loss. These options are not interchangeable, because the extent of bypass varies by route and drug. Route selection therefore requires attention to the expected systemic exposure and the desired timing or predictability of effect.
Hepatic Metabolism Bypass informs both dose selection and formulation by showing how the delivery route may change the amount of active drug reaching systemic circulation. A route that limits presystemic loss may increase bioavailability compared with oral delivery. Pharmacologists can use this relationship to support formulations and dosing approaches aligned with the intended exposure.
A comparison may be useful when investigators need to evaluate differences in bioavailability, onset, or predictability of drug effects. Oral delivery exposes a dose to portal entry and first-pass metabolism, whereas alternative routes can reduce that presystemic loss to varying degrees. Such comparisons help connect administration route with observed systemic drug exposure in pharmacology studies.